Crossmark

Aflibercept in diabetic macular edema refractory to previous bevacizumab: outcomes and predictors of success

Crossref DOI link: https://doi.org/10.1007/s00417-018-3951-7

Published Online: 2018-03-09

Published Print: 2018-07

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Călugăru, Dan

Călugăru, Mihai
License Information

Text and Data Mining valid from 2018-03-09
More Information

Article History

Received: 4 February 2018

Revised: 11 February 2018

Accepted: 1 March 2018

First Online: 9 March 2018

Compliance with ethical standards

:

: The authors declare that they have no conflict of interest.